Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
FDA granted IND clearance for ITIL-306, Instil’s first genetically-engineered CoStAR-TIL therapy for the treatment of…